Top insider buys and sells disclosed on Friday

US-listed company Grace Therapeutics, Inc. experienced significant insider buying on Friday, October 16, 2026, according to disclosed trading activity. Opaleye Management Inc., a 10% owner and director of the company, purchased approximately 11,233 shares of GRCE at an average price of $1.9349 per share, up to a maximum of $1.98.

This acquisition was made at a time when GRCE's stock was trading near its 52-week low of $1.79. Analysts have noted that GRCE appears undervalued, with price targets ranging from $3.92 to $7.88. Opaleye Management's purchase is seen as supportive of the company's prospects, as it currently trades at a low valuation amid positive analyst assessments.